why Hims & Hers Health Inc. [HIMS] is a Good Choice for Investors After New Price Target of $11.95

Hims & Hers Health Inc. [NYSE: HIMS] stock went on a downward path that fall over -2.98% on Tuesday, amounting to a one-week price decrease of less than -13.31%. The company report on February 27, 2023 that Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Full year 2022 revenue of $526.9 million, up 94% year-over-year.

Q4 2022 record revenue of $167.2 million, up 97% year-over-year.

Over the last 12 months, HIMS stock rose by 112.39%. The one-year Hims & Hers Health Inc. stock forecast points to a potential upside of 18.24. The average equity rating for HIMS stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $2.03 billion, with 206.16 million shares outstanding and 156.55 million shares in the current float. Compared to the average trading volume of 2.31M shares, HIMS stock reached a trading volume of 4889242 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Hims & Hers Health Inc. [HIMS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HIMS shares is $11.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HIMS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Hims & Hers Health Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 09, 2023. The new note on the price target was released on November 08, 2022, representing the official price target for Hims & Hers Health Inc. stock. Previously, the target price had yet another raise from $7.50 to $8.50, while BofA Securities kept a Buy rating on HIMS stock. On October 17, 2022, analysts decreased their price target for HIMS shares from 8 to 6.

The Average True Range (ATR) for Hims & Hers Health Inc. is set at 0.66, with the Price to Sales ratio for HIMS stock in the period of the last 12 months amounting to 4.58. The Price to Book ratio for the last quarter was 6.47, with the Price to Cash per share for the same quarter was set at 0.86.

HIMS Stock Performance Analysis:

Hims & Hers Health Inc. [HIMS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.31. With this latest performance, HIMS shares gained by 23.83% in over the last four-week period, additionally plugging by 60.43% over the last 6 months – not to mention a rise of 112.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HIMS stock in for the last two-week period is set at 54.29, with the RSI for the last a single of trading hit 49.34, and the three-weeks RSI is set at 56.82 for Hims & Hers Health Inc. [HIMS]. The present Moving Average for the last 50 days of trading for this stock 8.18, while it was recorded at 10.42 for the last single week of trading, and 6.17 for the last 200 days.

Insight into Hims & Hers Health Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Hims & Hers Health Inc. [HIMS] shares currently have an operating margin of -13.00 and a Gross Margin at +76.15. Hims & Hers Health Inc.’s Net Margin is presently recorded at -12.46.

Return on Equity for this stock declined to -20.32, with Return on Assets sitting at -16.69.

Hims & Hers Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 4.50.

Hims & Hers Health Inc. [HIMS] Insider Position Details

There are presently around $1,216 million, or 58.20% of HIMS stock, in the hands of institutional investors. The top three institutional holders of HIMS stocks are: VANGUARD GROUP INC with ownership of 11,320,410, which is approximately 1.846% of the company’s market cap and around 0.80% of the total institutional ownership; REDPOINT MANAGEMENT, LLC, holding 10,396,124 shares of the stock with an approximate value of $101.57 million in HIMS stocks shares; and INSTITUTIONAL VENTURE MANAGEMENT XVI, LLC, currently with $99.74 million in HIMS stock with ownership of nearly 0.072% of the company’s market capitalization.

Positions in Hims & Hers Health Inc. stocks held by institutional investors increased at the end of Monday and at the time of the Monday reporting period, where 76 institutional holders increased their position in Hims & Hers Health Inc. [NYSE:HIMS] by around 13,487,960 shares. Additionally, 68 investors decreased positions by around 6,768,941 shares, while 40 investors held positions by with 104,219,270 shares. The mentioned changes placed institutional holdings at 124,476,171 shares, according to the latest SEC report filing. HIMS stock had 27 new institutional investments in for a total of 2,007,910 shares, while 25 institutional investors sold positions of 5,424,466 shares during the same period.


Please enter your comment!
Please enter your name here